Long-term Data Needed for Xenical, Meridia and Acomplia
This article from about a week ago cuaght my eye on Yahoo. It is about the need for collecting long term safety data for two approved diet drugs in the US and another one tat is under review by the FDA. THe three drugs are Xenical (orlistat), Meridia (sibutramine) which are approved and Acomplia (rimonabant) which is under review. The article mentions an article in journal Lancet.
Long-term data needed on anti-obesity drugs - Yahoo! News:
I tend to agree especially since they all seem to have the potential for serious side effects which show up even with just short term use. As I have said here many times, they risk and reward need to be weighed for the use of any drug. There may be cases where the potential benefits outweighs the negative. However, my concern with drugs such as diet drug are the potential for misuse and over-prescribing of such drugs. Given Americans obsession with dieting and weight loss, these drugs have a huge potential for problems and I agree that more long term safety data is needed.
Long term safety data will likely be one of the primary topics for FDA reform this year from the Democrats in Congress especially in the House of Representatives.
Other Resources
XENICAL.com Home
Meridia (Sibutramine HCl)
Accomplia: The New Weight Loss Drug (Rimonabant)
Technorati Tags: Acomplia, Meridia, orlistat, Rimonabant, sibutramine, Xenical
Related Posts:
Bookmark it with:
| 
del.icio.us
| 
Digg it
| 
Furl
| 
Simpy
| 
Spurl
| 
My Yahoo!
|
July 24th, 2007 at 9:11 am
This is exactly what I expected to find out after reading the title Long-term Data Needed for Xenical, Meridia and Acomplia. Thanks for informative article